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1. Introduction 
Colorectal cancer (CRC) is an important health problem in many western countries due to 
its significant morbidity/mortality. Despite advances in its diagnosis and treatment, 
survival associated with this cancer when it has extended to adjacent organs, lymphatic 
nodules or distal organs is drastically reduced. The liver is the most common site of CRC 
metastasis, since it represents a unique microenvironment for the formation of metastases, 
not only due to its sinusoidal endothelium (Barberá-Guillén et al., 1989), but also due to its 
abundant expression of growth factors (GFs) (Stoeltzing et al., 2003). 
At present, curative treatment of localized metastases is possible via partial liver resection. 
However, this surgical procedure is only potentially curative, since 65% of patients 
subjected to resection of liver metastases experience relapse within 5 years (Sun & Tang, 
2003; Allendorf et al., 2004). In the light of this frequent recurrence, it is essential to develop 
new preventive therapeutic strategies, which require a detailed knowledge of the biological 
events that occur following hepatectomy. In this sense, we have previously demonstrated 
the tumor-enhancing effect associated with liver resection in a mouse tumor model; in 
addition, we showed that hepatectomized rat serum increased cell proliferation in vitro, 
when compared with laparotomized rat serum or fetal calf serum (García-Alonso et al., 
2003; García-Alonso et al., 2008a, 2008b). These findings indicated that GFs produced by the 
liver promote the development of metastases.  
At present, CRC treatment includes various active drugs, either as individual agents or in 
combination: 5-fluorouracil (5-FU), capecitabine, irinotecan and oxaliplatin, among others. 
Despite this wide array of anti-tumor agents, relapse often occurs in CRC patients, due in 
large part to the resistance of the tumor cells to these anti-neoplastic agents. Various 
different mechanisms have been reported as being responsible for the development of 
chemoresistance and, though each may be important in itself, they take on an even greater 
significance if we consider how they may be interrelated. 
One of these mechanisms of resistance to anti-neoplastic agents is the presence of GFs, 
which may be able to protect certain tumor cells against cytotoxic cell death. For this reason, 
one of the most promising cell targets nowadays are these GFs and their receptors. Thus, 
since 2004, three new agents have been approved which in combination with cytotoxic 
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agents are administered in cases of advanced and metastatic CRC: bevacizumab, a 
monoclonal antibody to vascular endothelial growth factor (VEGF) (Hurwitz et al., 2004), 
and cetuximab and panitumumab, which are monoclonal antibodies to the epidermal 
growth factor receptor (EGFR) (Cunningham et al., 2004; Odom et al., 2011). 
An increasing amount of evidence indicates that the intracellular redox state plays an 
essential role in the mechanisms underlying the actions of GFs. In particular, GFs have been 
reported to generate reactive oxygen species (ROS) which can function as second 
messengers, mediating important cellular functions, such as proliferation and programmed 
cell death. Intracellular redox homeostasis is sustained primarily by glutathione (GSH), 
which has long been known to be an important factor in cancer chemoresistance. 
In the present chapter, we analyze three important concerns in relation to CRC 
chemoresistance: 
 The influence of GFs in CRC biology and in the response to current cytotoxic therapies. 
 The involvement of the redox state in the mechanisms of action of GFs in CRC cells.  
 The exogenous modulation of the redox state as a new pharmacological strategy to 
improve the response to chemotherapeutic agents. 
2. Growth factors and colorectal cancer 
GFs play a fundamental role in CRC biology, mediating critical functions in cancerous cells, 
such as proliferation, angiogenesis and the inhibition of cell death. The recurrence of cancer 
after excision surgery is still a major clinical problem. Accumulating clinical and 
experimental evidence has indicated that specific factors involved in liver regeneration may 
influence the growth patterns of residual or dormant micrometastases after resection, 
suggesting that the process of hepatic regeneration has a significant proliferative effect on 
tumor cells. In this regard, GFs appear to be involved in tumor recurrence and in metastasis 
formation. Thus, after partial resection of liver metastases, various types of GFs, which are 
responsible for liver regeneration, are locally released. However, these may also stimulate 
the proliferation of undetected tumor cells in the remaining liver, i.e. highly metastatic colon 
cancer cells can respond to liver regeneration associated mitogens, whose expression is 
induced after hepatectomy. GFs such as hepatocyte growth factor (HGF), epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-), transforming growth factor beta 
(TGF-), basic-fibroblastic growth factor (b-FGF), insulin growth factor–I (IGFI) and vascular 
endothelial growth factor (VEGF) have been reported to be associated with tumor 
progression and metastasis (Christophi et al., 2008).  
Hepatocyte Growth Factor (HGF) is essential for the process of hepatic regeneration. It is a 
potent mitogenic agent produced by stellate, endothelial and Kupffer sinusoidal cells, which 
binds to a receptor of the tyrosine kinase (TK) family. This family of genes is encoded by the 
proto-oncogene c-Met which is expressed in hepatocytes, as well as in other cell types, 
including tumor cells (Di Renzo et al., 1991). It has a pro-angiogenic effect and stimulates 
cell motility as well as the secretion of matrix metalloproteinases (MMPs) by pericytes, 
suggesting an important role in tumor invasion. In the case of CRC, the co-expression of 
HGF and its receptor is correlated with tumor pathogenesis and with the metastatic 
phenotype, and for this reason, it has been proposed as a possible molecular marker to be 
incorporated into CRC staging procedures (Kammula et al., 2007). Moreover, it is known 
that epithelial tumor metastases undergo an epithelial to mesenchymal transition (EMT) 
before becoming invasive. The stimuli which promote this transition include HGF and other 
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GFs such as b-FGF, EGF, TGF-, as well as extracellular matrix (ECM) constituents including 
MMPs (Kalluri & Zeisberg, 2006; Christophi et al., 2008). For these reasons, HGF is 
considered to be a potentially valuable new therapeutic target for different tumors. Studies 
using NK4, a HGF antagonist, have shown an inhibitory effect on proliferation, invasion 
and angiogenesis in cell lines of gastric and pancreatic carcinoma, and of CRC (Hirao et al., 
2002; Wen et al., 2007). In addition, anti-HGF monoclonal antibodies have been developed, 
thereby blocking binding to its receptor (Cao et al., 2001). Other developments include anti 
c-Met antibodies (Jin et al., 2008), and strategies aimed at silencing the expression of c-Met 
or HGF via antisense oligonucleotides (Stabile et al., 2004), o iRNA (Shinomiya et al., 2004). 
Epidermal Growth Factor Receptor (EGFR) ligands, the most physiologically relevant of 
which include EGF, TGF-ǂ, and Amphiregulin (AR). All of these bind to the extracellular 
domain of EGFR, which is a member of the ErbB transmembrane TK receptor family (Hynes 
& Lane, 2005). Binding of these ligands to the receptor activates the Ras/Raf/MAPK and 
PI3K-AKT signaling pathways which are involved in tumor cell proliferation, inhibition of 
apoptosis, invasion, migration and angiogenesis (Le Golvan & Resnick, 2010; Wanebo & 
Berz, 2010). Abnormal expression of these ligands has been demonstrated in many 
advanced tumors, including breast cancers, gliomas, and lung cancer. In the case of CRC, 
EGFR overexpression has been detected in 60-80% of cases (Le Golvan & Resnick, 2010) and 
a correlation has been reported with early tumor recurrence and extra-hepatic metastasis 
(Christophi et al., 2008). However, its exact role in the CRC metastatic cascade has not yet 
been characterized due to controversial results obtained with anti-EGFR antibody therapy. 
In this regard, the therapeutic use of two monoclonal antibody agents (cetuximab and 
panitumumab) has been authorized in patients with metastatic CRC; although they have a 
modest effect when used as single agents, they have been found to be beneficial in some 
patients when used in combination with conventional chemotherapeutic agents (Wanebo & 
Berz, 2010; Tol & Punt, 2010). In fact, it has been shown that the response to this therapy is 
independent of EGFR expression in tumor tissue (Chung et al., 2005). Thus, some studies 
suggest that EGFR expression in the primary tumor does not necessarily correspond with 
the same level of expression in metastatic tissue, while other studies have reported 78-100% 
concordance in EGFR expression in both tissue compartments (Tol & Punt, 2010). These 
discrepancies may partially be due to differences in the detection techniques employed. 
Nevertheless, recent studies have demonstrated that the therapeutic efficacy of the anti-
EGFR antibody is limited to patients in whom the K-Ras oncogene is not mutated, since 
mutation of this oncogene can induce constitutive activation of the Ras/Raf/MAPK 
signaling pathway, which is independent of the activation of EGFR via ligand binding 
(Benvenuti et al., 2007; Tol & Punt, 2010). 
Transforming Growth Factor β (TGF-β) acts as a tumor suppressor due to its inhibition of 
growth and its activation of apoptosis. However, in CRC, this suppressor activity is lost due 
to the existence of mutations in the genes which encode TGF-ǃ, the type II receptor (TGFR ǃ 
2), or SMAD proteins, in such a way that the antiproliferative signal associated with this 
factor is interrupted (Markowitz & Bertagnolli, 2009). On the other hand, TGF-ǃ has a pro-
tumor effect due to its effect on the stroma, promoting angiogenesis, and on the tumor cells 
themselves, stimulating their motility and their invasive capacity (Blobe & Gordon, 2000). 
Thus, TGF-ǃ, whose serum values are correlated with a poor CRC prognosis, acts as a tumor 
promoter, inducing the development of hepatic metastasis (Shim et al., 1999). 
Insulin Growth Factor I (IGF-I) and its TK receptor are implicated in the development and 
progression of CRC due to their induction of proliferation. A correlation has been found 
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between serum levels of IGF-I, high levels of IGF-IR expression in tumor cells and the 
development of hepatic metastasis. This pro-tumor effect is due to the fact that the signal 
induced by the binding of IGF-I to its receptor promotes the migration of endothelial cells, 
invasion and the formation of new blood vessels following the stimulation of VEGF 
production by endothelial cells (Wu et al., 2002), suggesting that IGF-I is an important 
contributor to tumor growth and hepatic metastatic development after hepatectomy 
(Christophi et al., 2008). 
Vascular Endothelial Growth Factor (VEGF) is an endothelial cell mitogen which induces 
cell migration, proliferation, invasion and increased vascular permeability and has a potent 
pro-angiogenic activity. It has been shown that a large percentage of tumors which produce 
high levels of VEGF are associated with a high density of vessels in the tumor, metastasis, 
chemoresistance and poor prognosis (Sullivan & Brekken, 2010). 
The VEGF family is made up of six growth factors. These exert their effects via binding to 
one of the three VEGFRs which belong to the tyrosine kinase receptor (TKR) family. These 
are localized predominantly on endothelial cells and angioblasts (Tol & Punt, 2010). In 
addition, in solid tumors, it is postulated that the production of VEGF is increased following 
liberation of hypoxia-inducible factor 1ǂ (HIF-1ǂ) (Kaur et al., 2005), EGF (Niu et al., 2002) 
and HGF (Dong et al., 2001). In turn, VEGF induces the synthesis of other factors related to 
tumor development, such as stroma-derived factor 1 (SDF-1) which induces an increase in 
the population of cancer-associated fibroblasts (CAFs) (Kalluri & Zeisberg, 2006, Christophi 
et al., 2008). 
The risk of developing hepatic metastasis associated with CRC may be related to the 
expression of different VEGF isoforms which bind to the different VEGFRs. Thus, it has 
been shown that in 50% of CRCs, VEGFR-2 is expressed on the surface of the tumor cells 
(Duff et al., 2006). This extensive expression, which reflects the dependence of some solid 
tumors on neoangiogenesis, has led to the proposal that VEGF and VEGFR may be 
therapeutic targets in the treatment of CRC. Bevacizumab is a humanized monoclonal 
antibody which binds to VEGFA blocking the binding of this GF to VEGFR, thereby 
avoiding the corresponding intracellular signal transduction. Although parameters which 
allow a prediction of the efficacy of this monoclonal antibody have not been reported, 
bevacizumab has been approved as a first and second-line therapy for the treatment of 
metastatic CRC, enhancing survival, stabilizing the disease and achieving partial regression 
when used with chemotherapy. Two recent and complete reviews by Tol & Punt (2010) and 
Wanebo & Berz, (2010) analyze randomized and non-randomized trials of neo-adjuvant 
therapy using bevacizumab in metastatic CRC. 
3. The role of the redox state in the mechanism of action of growth factors 
The redox state is a key characteristic which influences important cell biological processes 
including enzymatic reactions, cell signaling, cell proliferation and apoptosis. The term 
redox signaling refers to a regulatory process in which the signal is transmitted through 
redox reactions. The intra- and extracellular redox levels allow the carrying out of different 
extra and intracellular signaling (intra-cytoplasmic and nuclear), which subsequently give 
rise to the cascade of effector signals that regulate diverse cellular activities such as cell 
proliferation. 
GF signals are transmitted from the cell surface by means of the activation of TK-type 
transmembrane receptors and the induction of the corresponding intracellular effects. 
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Among these signal transduction pathways, protein phosphorylation plays a fundamental 
role. This process is reversible and dynamic, being controlled by the opposing actions of 
protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). As a consequence 
of the binding of GF to its specific receptor, dimerization occurs followed by the 
autophosphorylation of tyrosine residues in the intracellular domain of the receptor 
(Cadena & Gill, 1992). These residues are key sites of interaction with cytoplasmic proteins 
which contain SH2 (Src homology type 2) domains; these mediate the signal transduction of 
GFs, such as PLC- Ǆ, GAP-ras (GTP-ase-activating protein of ras), PIK3 and Grb2 (Johnson & 
Vaillancourt, 1994). The action of all these proteins, via different mechanisms, converges to 
activate the Ras protein, which in its turn, activates the Raf tyrosine. Subsequently, a 
phosphorylation cascade is produced in such a manner that Raf phosphorylates another 
kinase, the MAPK kinase which phosphorylates members of a family of serine/threonine 
kinases, the MAP kinases. Finally, MAP kinases phosphorylate the transcription factors 
which promote the transcription of genes necessary for the final cellular response (Davis, 
1993). 
Many studies have demonstrated that the cellular redox status plays a key role in GF-
mediated signaling systems (Thannickal & Fanburg, 2000). Although there is evidence that 
GFs generate ROS, it is not yet clear how ROS activate these cell signaling pathways. One 
plausible mechanism is that ROS could act as second messengers which participate in 
phosphorylation/dephosphorylation processes (Storz, 2005). ROS, such as hydrogen 
peroxidase (H2O2), induce the phosphorylation and activation of some PTKs, such as the 
kinases implicated in the MAP kinase cascade (Rao, 1996). In contrast, PTPs have a cysteine 
residue in their catalytic domain, which must be in its reduced form for total activity of the 
receptor. It has been shown that in cell signaling phenomena, ROS may induce the 
inactivation of PTPs (Rhee et al., 2000). Interestingly, ROS play a crucial role in vascular 
angiogenesis, not only due to their induction of VEGF (Sen et al., 2002), but also to their 
implication in the VEGF signaling pathway. Thus, VEGF stimulates ROS production via the 
activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is 
essential for the satisfactory propagation of the angiogenic signal (Roy et al., 2008); in fact, 
NADPH oxidase has been proposed as a target for anticancer therapy (Ushio-Fukai & 
Nakamura, 2008). 
Similarly, it has been demonstrated that EGF stimulates ROS production in cells and that 
inhibition of this production leads to a weakening of the signaling system of the 
corresponding factor (Mills et al., 1998). A ROS mediated signaling cascade has also been 
reported to be activated following stimulation of the c-Met/HGF system; this cascade has 
been found to be associated with the crucial role of the receptor in the development of 
metastasis (Ferraro et al., 2006). 
All of these biological effects occur at low to moderate concentrations of ROS. For this 
reason, redox regulation is essential for the maintenance of an optimal level of oxidation 
which permits precise signal transduction and the appropriate cellular response.  
4. Glutathione metabolism in colorectal cancer 
Cells are exposed to oxidative stress which is generated by normal metabolism and also by 
exogenous factors, such as ionizing radiation, some chemotherapeutic drugs and 
xenobiotics. The oxidative modification of cell components via ROS is one of the most 
potentially damaging processes for normal cellular activity (Halliwell, 1991). However, ROS 
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are well recognized for playing a dual role. Thus, a number of studies have provided 
convincing evidence that, depending on the level of oxidative stress, ROS can function as 
pro-life signals in certain contexts (as mentioned above, low or mild increases in ROS play a 
pivotal role in many physiological reactions, such as the regulation of transcription factors 
and cellular signaling pathways) (Maellaro et al., 2000) and pro-death signals in others (high 
concentrations of ROS can induce apoptosis) (Le Bras et al., 2005). Consequently, the 
maintenance of the redox status is a key factor for cell survival, in the case of both normal 
and cancer cells. 
In order to maintain redox balance and also to protect themselves from oxidative stress, cells 
possess powerful redox regulation systems, known as the “redox buffer”, including GSH and 
thioredoxin (TRX), as well as antioxidant enzymes, such as superoxide dismutase (SOD), 
catalase, GSH peroxidase (GPx) and thioredoxin reductase (TrxR). In addition, cells also 
have available other non-enzymatic antioxidants which are obtained via the diet, among 
which are ascorbic acid (vitamin C), ǂ-tocopherol (vitamin E), flavonoids, carotenoids and 
selenium. 
Intracellular redox homeostasis is sustained primarily by GSH, the most prevalent intracellular 
non-protein thiol. In fact, the ratio between its reduced and oxidized states (GSH/GSSG) is 
considered to be an indicator of the redox status of the cell. GSH is intracellularly synthesized 
from the three amino acids glutamic acid, cysteine and glycine; it possesses an unusual  
peptide bond between glutamic acid and cysteine, and has a thiol group on the latter 
aminoacid. The biosynthesis and degradation of GSH occurs within the -glutamyl cycle, in 
which GSH is transported to the extracellular space and -glutamyl-aminoacids are 
transported to the intracellular space. GSH is synthesized from glutamate by two consecutive 
reactions which are catalyzed by the -glutamylcysteine synthetase (-GCS) and GSH 
synthetase enzymes. GSH can be exported outside the cell, although its constituent aminoacids 
can be reincorporated into the cell, thanks to a transpeptidation reaction catalyzed by the -
glutamyl transpeptidase (-GT) enzyme, which is a glycoprotein localized on the outer surface 
of the plasma membrane. Transpeptidation occurs in the presence of aminoacids, giving rise to 
-glutamyl-aminoacids and cysteinylglycine (Cys-Gly). The -glutamyl-aminoacids are 
transported into the cell, whereas in the case of cysteinylglycine, bond breakage by means of a 
dipeptidase is first required. This dipeptidase is present on the outer surface of the plasma 
membrane, thereby allowing the incorporation of the peptides into the cell. The -glutamyl-
aminoacids are the substrate of the -glutamyl cyclotransferase enzyme, which transforms the 
glutamyl residue into 5-oxoproline, liberating the remaining aminoacids. Next, by means of 
the 5-oxo-L-prolinase (5-OPase) enzyme, 5-oxoproline is transformed into glutamate and this 
reaction involves the consumption of ATP. The cycle is completed with the action again of -
GCS and GSH synthetase (Fig. 1) (Meister & Anderson, 1983). 
Due to its structural characteristics, GSH participates in numerous processes which are 
essential for cell physiology. GSH and its related enzymes are involved in cell proliferation 
and participate in the cell cycle, in the synthesis of proteins and in DNA synthesis and repair 
(Higuchi, 2004). In addition, its capacity as a reducing and antioxidant agent renders GSH 
an essential component for the maintenance of the integrity of the protein and lipid 
components of the cell, as well as a substrate for antioxidant GSH peroxidase enzymes, a 
selenium-dependent system. As indicated previously, another of its important functions 
consists in the protection of the cell from free radicals, endogenous and exogenous toxic 
substances, and carcinogens. GSH also defends the cell against the effects produced by 
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radiation and some chemotherapeutic drugs, such as alkylating agents. The formation of 
GSH S-conjugated products generated during intracellular detoxification may occur due to 
the non-enzymatic reaction of exogenous electrophilic compounds or to the action of GSH S-
transferase (GST) enzymes. GST conjugates can then be eliminated via an ATP-dependent 
GS-X pump. 
 
 
Fig. 1. The Ǆ-glutamyl cycle. Abbreviations: -glu-AA, -glutamyl-aminoacids; Glu, glutamic 
acid; Cys, cysteine; Gly, glycine.  
In addition to its essential role in normal growth, GSH is also involved in cell differentiation. 
Thus, it has been reported that as the cell progresses from proliferation to differentiation, 
cellular GSH content decreases. For example, it has been observed that butyrate-induced 
differentiation of the HT-29 human colon cell line is associated with reduced levels of cellular 
GSH (Bernard & Balasubramanian, 1997). These findings led to the notion that thiol status may 
be dependent on cellular energy metabolism. In this regard, the tumor cells have a very high 
cellular metabolism and, consequently, they generate high levels of ROS. Here, we should 
underline the importance of regulation of redox balance for the survival of malignant cells; the 
activation of redox regulatory systems, in which GSH plays an important role, could be 
considered to be the first line of adaptation of cancerous cells to oxidative stress. In fact it has 
been reported that non-differentiated and highly metastatic melanoma cells have a 
significantly higher GSH content than non-tumorigenic melanocytes (Thrall et al., 1991). 
Moreover, it has been demonstrated that whereas elevation of intracellular GSH is associated 
with mitogenic stimulation (Palomares et al., 1997), GSH depletion decreases the rate of cell 
proliferation and inhibits cancer growth (Del Olmo et al., 2000).  
Increased levels of ROS in cancerous cells may have profound consequences, including 
enhanced cell proliferation, increased incidence of mutations and genetic instability, and 
reduced sensitivity of cells to anticancer agents, leading to resistance. In the case of CRC, 
intense oxidative stress and significant oxidative DNA adducts have been found during all 
stages of colorectal carcinogenesis (Schmid, et al., 2000). In fact, these DNA adducts, as well 
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as GST polymorphisms, have been suggested as molecular biomarkers for the detection of 
early CRC and the prediction of the clinical effectiveness of chemopreventive drugs (Garcea 
et al., 2003). Elevated GST expression (Naidu et al., 2003) and a significant increase in GSH 
levels (Balendiran et al., 2004) have been found in CRC; these are often associated with an 
increased resistance to cancer chemotherapy drugs via GSH conjugation. Elevated GSH 
levels may also be related to Ǆ-GCS, another GSH-related enzyme whose levels have also 
been found to be elevated in CRC (Tatebe et al., 2002). Finally, it should be remembered that 
GSH and its related enzymes is only one of the redox regulation systems which are 
implicated in CRC, since an increased expression of TRX-1 in human CRC has been found to 
be associated with reduced survival times of patients (Raffel et al., 2003). 
In summary, the GSH system involves complex and dynamic processes in which several 
related enzymes participate. Although it may be difficult to know a priori what type of GSH 
metabolism a given CRC may have, the fact that some CRC cells contain high levels of GSH 
has led to the suggestion that it may be an important factor in limiting the therapeutic 
efficiency of conventional cancer treatment. 
5. The influence of glutathione metabolism in the response to chemotherapy 
A common cause of treatment failure in CRC is chemoresistance. This resistance to current 
cytotoxic therapies limits their success in the majority of advanced cancer patients. This is 
particularly true in the case of liver metastases.  
GSH is able to modulate cell susceptibility to chemotherapy. In particular, GSH plays an 
important role in the protection against cell injury caused by various anticancer agents (see 
Balendiran et al., 2004 for review), and elevated GSH levels render tumor cells resistant to 
chemotherapeutic drugs. In the particular case of CRC, there is also evidence that the GSH 
status of colon cancer cells is a critical determinant of cell damage by various agents. Indeed, 
it has been proposed that elevated intracellular GSH levels may be a cause of acquired 
resistance to 5-FU, platinum agents and camptothecins. In this regard, it has been suggested 
that the increased levels of antioxidant enzymes in response to the generation of ROS by 5-
FU, a standard drug for the treatment of this disease, may underlie the acquired resistance 
to this anti-tumor agent (Hwang et al., 2007). In in vitro studies, we have shown that 
treatment with 5-FU produced the greatest antiproliferative effect after 24 hours of 
incubation and that later, once drug treatment had been stopped, the growth of tumor cells 
rebounded (Palomares et al., 2009). This finding may be due to the recovery of GSH levels 
after the initial 5-FU-induced reduction, which has also been suggested by other authors 
(Chen et al., 1995). 
It has also been reported that GSH may modulate the cytotoxicity of platinum agents 
(Sadowitz et al., 2002). However, intracellular GSH levels do not appear to influence the cell 
growth-inhibiting activity of these compounds in cells not previously exposed to platinum 
complexes (Boubakari et al., 2004), suggesting that GSH may be more relevant in acquired 
resistance. Furthermore, several authors have reported the influence of GSH on sensitivity 
to camptothecins (Yoshida et al., 2006). 
In order to decrease the resistance of tumor cells to chemotherapeutic drugs, many GSH-
based therapeutic strategies have focused on lowering GSH levels, principally via the use of 
agents which reduce this tripeptide or inhibit its synthesis. The agent which is most 
frequently used to reduce the levels of this thiol, not only in basic research but also in 
clinical assays, is L-buthionine-S,R-sulfoximine (BSO) (Fig. 2). We found that this potent 
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inhibitor of Ǆ-GCS enhances the sensitivity of tumor cells to treatment with ionizing 
radiation and cytostatic drugs, such as alkylating agents (Palomares et al., 1999). We have 
also found that the reduction in GSH content (around 52%) produced by BSO significantly 
inhibits the proliferation of colon cancer WiDr cells (Palomares et al., 2009). 
 
 
Fig. 2. Inhibition of -glutamylcysteine synthetase by L-buthionine-S,R-sulfoximine (BSO). 
However, the anti-tumor efficacy of BSO is accompanied by increased toxicity, due to the 
fact that BSO exerts its effects in a non-selective manner. In fact, it reduces GSH levels in 
both tumor and normal cells and thus sensitizes both cell populations to the toxic effect of 
anticancer agents. This finding has been reported in clinical studies, such as that of Bailey et 
al. (1998), who upon combining BSO and melphalan, found an important increase in 
medullar toxicity with respect to that produced by the administration of the alkylating agent 
alone. Thus, BSO treatment produces toxicity at the level of the immune, gastrointestinal, 
urinary and central nervous systems. This toxicity limits, de facto, the therapeutic potential of 
BSO and of other non-selective GSH reducing agents. 
One of the principal reasons for the limited effects of chemotherapy is the insufficient 
therapeutic index of available drugs. This index could be increased by regimes which 
protect healthy tissues against toxicity and at the same time enhance the sensitivity of tumor 
tissue to anticancer drugs. Since GSH is highly relevant in protecting both normal and 
tumor cells, one way of achieving this objective would be to selectively modulate GSH 
levels. An increase in GSH levels or in the capacity of normal cells to synthesize GSH, would 
enhance their resistance, leading to a protector effect. In contrast, a reduction in GSH 
content or in the capacity of tumor cells to synthesize this tripeptide would enhance 
sensitivity to the effects of anti-tumor agents. In this regard, it was suggested many years 
ago that agents which induce a selective modulation in GSH levels could be beneficially 
added to conventional treatments in order to enhance the anti-tumor efficacy of 
radiotherapy and/or chemotherapy (Russo et al., 1986). 
Selective modulation of GSH as a therapeutic strategy requires an in-depth knowledge of 
the physiological differences in GSH synthesis and metabolism between healthy and tumor 
cells, as well as of the level of expression of GSH-related enzymes. In this regard, lower 
expression of the 5-OPase enzyme has been found in some tumor cell lines in comparison to 
healthy cells, leading to the suggestion that this enzyme may be a key player in obtaining 
the required selective modulation of GSH (Chen & Batist, 1998). 
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Within the -glutamyl cycle, 5-OPase catalyses the hydrolysis of 5-oxo-L-proline to L-
glutamate, one of the three aminoacids which participate in GSH synthesis, joining in this 
way the reactions of GSH synthesis and metabolism in this cycle (see Fig. 1). It has also been 
observed that L-2-oxothiazolidine-4-carboxylate (OTZ) –an analog of 5-oxo-proline– also 
acts as a substrate of 5-OPase, thereby converting this cysteine prodrug into S-
carboxycysteine, hydrolyzing it subsequently to cysteine and CO2 (Fig. 3). 
Some studies have found that in contrast to BSO, OTZ treatment is selective, increasing GSH 
levels in healthy tissue and reducing it paradoxically in tumor tissue (Chen & Batist, 1998). 
These authors have suggested that OTZ, by competing with 5-oxo-L-proline for 5-OPase, 
could exert two different effects on GSH levels, depending on the level of expression of the 
5-OPase enzyme and on the quantity of aminoacids necessary for the synthesis of the said 
tripeptide. In this way, OTZ would increase intracellular levels of GSH in healthy cells by 
means of increasing the contribution of cysteine – in normal conditions, the limiting 
aminoacid in GSH synthesis in these cells - (Meister A, 1983), but would reduce GSH 
content in tumor cells by means of the inhibition of glutamate synthesis from 5-oxo-L-
proline. In fact, it has been observed that in tumor cells and in other cells under conditions 
of oxidative stress, glutama`te is the limiting factor in GSH synthesis (Kang, 1993) 
 
.  
Fig. 3. Metabolism of L-2-oxothiazolidine-4-carboxylate (OTZ) and of 5-oxo-L-proline by 
means of the 5-OPase enzyme. 
In in vitro studies, OTZ has been found to be useful as a protector in human lymphocytes 
against toxicity due to nitrogenated mustard, or in cultures of human fibroblasts against 
radio-induced toxicity. In in vivo studies using mouse models, OTZ has demonstrated its 
efficacy in protecting against liver damage produced by alcohol, by reducing the degree of 
cystitis induced by cyclophosphamide (CY) or of hepatotoxicity produced by 
acetaminophen, among others. OTZ has been used in diverse clinical assays for the 
treatment of a variety of pathologies associated with ROS generation and with reduced GSH 
levels. Diseases in which OTZ treatment has been successfully employed include acute 
respiratory distress syndrome (Morris et al., 2008), amyotrophic lateral sclerosis (Cudkowicz 
et al., 1999) and atherosclerosis (Vita et al., 1998). Patients subjected to peritoneal dialysis 
(Moberly et al., 1998) and patients infected with the AIDS virus (Barditch-Crovo et al., 1998) 
have also benefited from this treatment. 
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Paradoxically, in contrast to the effect produced in healthy tissue, OTZ reduces GSH levels 
in some human tumor cell lines including breast adenocarcinoma and ovary 
adenocarcinoma (Chen & Batist, 1998). In the same way, we have also demonstrated the 
selective character of GSH modulation by OTZ, in vitro as well as in vivo. Thus, OTZ was 
found to reduce the intracellular content of GSH in melanoma cells, producing reduced 
proliferation and increased chemosensitivity, whereas it increased GSH levels in peripheral 
blood mononuclear cells, exhibiting a corresponding cytoprotector effect (Del Olmo et al., 
2000, 2006; Bilbao et al., 2002). 
Several authors have pointed to the usefulness of GSH modulating agents as an adjuvant in 
chemotherapy treatments for CRC. Regarding 5-FU, a number of studies support the 
therapeutic use of antioxidant compounds in combination with this drug. Thus, therapy 
with high doses of antioxidants such as pyrrolidine dithiocarbamate (PDTC) and N-
acetylcysteine (NAC) seem to enhance the therapeutic efficacy of 5-FU (Bach et al., 2001). 
NAC is a prodrug of cysteine, which is an essential element for GSH synthesis. It was 
developed to avoid the important toxicity produced as a consequence of the direct 
administration of this aminoacid. The mechanisms of protection of this thiol against 
mutagenesis and carcinogenesis are related to a large number of biological effects, including 
antioxidant activity, involvement in DNA repair mechanisms, modulation of gene 
expression and of signal transduction, immunological activity, regulation of cell survival 
and of apoptosis, inhibition of cell transformation, of invasion and metastasis and of 
angiogenic activity, among others (Morini et al., 1999). However, some authors have 
reported contradictory effects of NAC in its anticancer action. Moreover, it has been 
demonstrated that antioxidant protection therapy in cancer patients should be used with 
caution, since it can give rise to counterproductive effects (Brizel & Overgaard, 2003). The 
reduction in the concentration of free radicals due to the excessive administration of 
antioxidants can stimulate the survival of damaged cells, enhancing the neoplastic stage, 
thereby promoting carcinogenesis more than inhibiting it. Furthermore, we and others have 
demonstrated that the increase in GSH levels induced by NAC is not specific to normal cells; 
rather, this can also occur in tumor cells, such as melanoma, increasing its proliferative 
capacity and protecting it against the cytotoxic effects of acrolein, one of the active 
metabolites of CY (Del Olmo et al., 2000).  
It has also been found that the reduced levels of GSH induced by BSO and OTZ, lead to an 
increased cytotoxic effect of 5-FU in different human CRC cells (Meurette et al., 2005; 
Palomares et al., 2009). It has also been observed that BSO enhances the activity of SN-38 (an 
active metabolite of the anticancer drug irinotecan) in WiDr colon cancer cells (Caramés et 
al., 2010), and in cell lines of ovary cancer resistant to cisplatin, as well as of breast cancer. 
BSO is also capable of reverting resistance to SN-38 in leukemia cells with increased GSH 
levels (Yoshida et al., 2006). This increased anti-tumor effect of SN-38 may be related to the 
reduced activity of the transcription factor NF-κB, which is dependent on the intracellular 
redox status and thus sensitive to a reduced content of intracellular GSH. In fact, SN-38 is 
known to activate NF-κB and so the pharmacological inhibition of this NF-κB signaling 
pathway can enhance the anti-tumor activity of SN-38 in colon cancer cells in vitro and of 
irinotecan in vivo (Lagadec et al., 2008). 
Regarding platinum compounds, various authors have demonstrated that GSH participates 
in the detoxification of these agents and that reduced GSH levels sensitize cancer cells to the 
cytotoxic effects of these anti-tumor agents (Jansen et al., 2002). We have found that both 
BSO and OTZ increase the efficacy of oxaliplatin in the WiDr human colon cancer cell line 
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(Caramés et al., 2010). Thus, reduced GSH levels mediated by BSO or OTZ lead to an 
increase in cytotoxicity induced by drugs which are more frequently used nowadays for 
CRC therapy, with an additive effect being observed in the antiproliferative effects of these 
combinations.  
6. The influence of growth factors in the sensitivity of tumor cells to 
chemotherapy 
Research on the phenomenon of chemotherapy resistance has traditionally focused on the 
tumor cells themselves. However, it has become apparent that the tumor microenvironment 
may also influence chemoresistance in an important way. In this regard, it is necessary to 
underline the fundamental role of GFs in cancer biology and in the formation of metastasis, 
since they control critical functions in cancer cells, such as proliferation, angiogenesis and 
the inhibition of apoptosis. Thus, GFs, due to their capacity to modulate the sensitivity of 
tumor cells to cytotoxic drugs, have become important targets for the development of new 
anti-cancer therapies, either as individual agents or in combination with conventional 
chemotherapy, with the aim of enhancing the efficacy of anti-cancer drugs.  
It has been demonstrated that the presence of GFs significantly reduces the cytotoxic activity 
of a number of commonly used drugs. In this regard, some authors have pointed out that 
HGF protects tumor cells against the cytotoxicity and apoptosis induced by DNA-damaging 
agents, such as ionizing radiation or adriamycin (Shen et al., 2007), and that it may 
contribute to the resistance of RMS cells to conventional treatment (Jankowski et al., 2003). 
Similarly, it has been suggested that this factor could induce resistance to cisplatin in lung 
cancer cells (Chen et al., 2008). Nevertheless, in contrast to expectations, it has also been 
observed that HGF sensitizes ovary cancer cells to the drugs paclitaxel and cisplatin 
(Bardella et al., 2007). These findings indicate that HGF effects depend on the targeted 
tumor type. Indeed, various other studies have reported the effect of VEGF in reducing the 
efficacy of endocrine therapy in breast cancer (Qu et al., 2008). It has also been found that 
VEGF diminishes the response to drugs in myeloid leukemia (De Jonge et al., 2008) and that 
doxorubicin exerts a milder inhibitory effect in the presence of VEGF overexpression in soft-
tissue sarcoma (Zhang et al., 2006). Regarding EGF, it has been widely demonstrated that 
this GF reduces the response of tumors, such as human breast carcinoma, to cytotoxic 
compounds and to radiotherapy (Schmidt & Lichtner, 2002). 
In the case of CRC, we (Palomares et al., 2009) and others (Sun & Tang, 2003; Allendorf et 
al., 2004) have demonstrated that HGF, EGF and VEGF significantly reduce the efficacy of 
drugs currently used in CRC. In particular, the increased expression of HGF and VEGF 
results in fluoropyrimidine-based adjuvant chemotherapy being less effective, increasing the 
risk of recurrence. In relation to EGF, it has been shown that its receptor, EGFR, increases 
resistance to 5-FU. Moreover, 5-FU itself induces the activation of EGFR, which protect 
colon cancer cells against chemotherapy (Hiro et al., 2008). Moreover, it has been reported 
that SN-38, through a mechanism involving ROS, induces the activation of EGF and EGFR, 
and this could contribute to resistance to irinotecan (Kishida et al., 2005). These data suggest 
that inhibition of the EGFR signaling pathway could revert resistance to treatment with the 
fluoropyrimidines and irinotecan. On the basis of this hypothesis, some authors have 
carried out assays using tyrosine kinase inhibitors of EGFR, such as gefitinib (Stebbing et al., 
2008), as well as inhibitors of the Src tyrosine kinase (Ischenko et al., 2008). 
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The molecular mechanisms underlying GF-mediated resistance continue to be largely 
unknown. On the one hand, GFs induce cell proliferation and the activation of anti-
apoptotic signaling pathways, via proteins such as Bcl-XL, thereby contributing to the 
resistance to apoptosis in CRC cells following treatment with 5-FU, oxaliplatin and 
irinotecan (Schulze-Bergkamen et al., 2008). In addition, it has also been suggested that GFs 
may also induce an increase in the repair of damaged DNA (Hiro et al., 2008). On the other 
hand, it has been observed that the EGFR-Src-STAT3 oncogenic signaling pathway plays an 
important role in CRC, contributing to proliferation, cell survival and treatment resistance 
(Hbibi et al., 2008). In fact, it has been demonstrated that this pathway is activated in 
response to treatment with topoisomerase I inhibitors, such as camptothecins, reducing 
DNA damage and enhancing cell survival (Vigneron et al, 2008). 
Moreover, as we have recently shown, GFs give rise to an increase in GSH levels which, as 
mentioned earlier, is an important mechanism of cell defense against oxidative stress and 
against the effects produced by radiation and by some chemotherapeutic agents; this 
increase in GSH levels has been correlated with diminished 5-FU anti-tumor activity in 
colon cancer cells (Palomares et al., 2009). In this regard, it has been reported that the 
combination of an EGFR inhibitor with doxorubicin leads to enhanced cytotoxic effects via 
the generation of oxidative stress, due to ROS induction and reduced GSH content in rat 
hepatoma cells (Ortiz et al., 2008). 
Additionally, it has been suggested that GF-induced increases in intracellular GSH levels 
and the activation of the redox-sensitive transcription factor NF-κB could play a major role 
in inducible chemoresistance. This cell survival transcription factor, which is subject to 
regulation by GSH (Lou  Kaplowitz, 2007), has been shown to be constitutively activated 
in many colon cancer cells. NF-κB has been shown to be associated with the proliferation of 
tumor cells, with invasion, angiogenesis and the production of metastasis (Bours et al., 
1994). It has been demonstrated that HGF, via the PI3K/Akt signaling pathway, leads to the 
activation of NF-κB, by means of which cells are protected against adriamycin and 
irinotecan (Fan et al., 2005). In the same way, the transmission of the proliferative signal 
induced by EGF is also mediated by the activation of NF-κB (Sethi et al., 2007), which plays 
an important role in the regulation of EGFR ligands via a ROS-mediated mechanism 
(Murillo et al., 2007). Moreover, NF-κB activation in response to exposure to anti-cancer 
drugs has been shown to be one of the mechanisms of tumor resistance to chemotherapy, as 
has been reported in the cases of 5-FU and irinotecan (Ahn et al., 2008). In contrast, 
inhibition of NF-κB has been shown to enhance the sensitivity of colon cancer tumor cells to 
HT-29 and 5-FU (Voboril et al., 2004). 
Overall, these data indicate that GFs play a critical role in the resistance of colon cancer cells 
to chemotherapeutic agents. In consequence, these factors are potential therapeutic targets 
for increasing the anti-tumor activity of cytotoxic drugs.  
7. New therapeutic strategies to enhance the response of CRC to 
chemotherapy by reversion of the growth factor pro-tumour effects 
Based on the aforementioned data, GFs have been identified as important targets to be 
considered in the development of new anticancer drugs and, consequently, many 
experimental studies have been carried out to evaluate the effects of blocking GF effects on 
tumor cells. These attempts could be classified into three categories, according to the 
mechanism chosen to avoid the GF stimulation of these cells. The first approach was to 
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administer monoclonal antibodies (MoAb) against one or several GFs, and the results have 
been quite exciting. Another idea was to produce MoAb against the membrane receptors for 
different GFs, and again the results have been very promising. In fact, several of these 
MoAb have already entered the armamentarium for cancer therapy and others are currently 
at different stages of clinical trials. The third exciting arm of these GF-based therapies 
consists of the so-called "small molecules" which block the activation of the intracellular part 
of GF receptors.  
The combination of conventional cytotoxic drugs with new agents that specifically interfere 
with GF signaling pathways presents the advantage of avoiding crossed resistance, since 
these approaches are directed against different cell targets and have different underlying 
mechanisms of action. In this regard, many studies have indicated that inhibitors of GFs or 
of their receptors enhance the efficacy of conventional cytotoxic agents (Wanebo & Berz, 
2010). The GF inhibitors bevacizumab and cetuximab are particularly noteworthy. 
Currently, bevacizumab is used in combination with regimes which contain 5-FU (FOLFOX 
or FOLFIRI) as a first line therapy in advanced or metastatic CRC (Giantonio et al., 2007; Tol 
& Punt, 2010). On the other hand, combined therapy consisting of irinotecan and cetuximab 
is indicated after progression in patients who have previously received 5-FU based therapy 
(Cunningham et al., 2004). 
Other agents, such as gefitinib, have been found in preclinical studies to exhibit synergistic 
inhibitory effects when administered in combination with different cytotoxic drugs. For 
example, some authors have observed that gefitinib and irinotecan act synergistically in 
WiDr cells, as a result of the inhibition of the survival signal induced by irinotecan via the 
phosphorylation of EGFR (Koizumi et al., 2004). Similarly, in vitro studies have shown that 
the combination of gefitinib and oxaliplatin has a synergistic effect in colon cancer cells due, 
at least in part, to the fact that the EGFR inhibitor reduces the activity of Ǆ-GT. This enzyme, 
which participates in the Ǆ-glutamyl cycle, helps to salvage extracellular GSH and 
contributes to redox control by providing a substrate for GSH synthesis during oxidative 
stress, thereby preventing apoptosis, as we have showed previously (Castro et al., 2002). 
Reduced Ǆ-GT activity thereby leads to increased cellular oxaliplatin accumulation and 
platinum-DNA adducts (Xu et al., 2003). 
However, these anti-tumor agents also have their inconveniences. They induce diverse side 
effects which complicates their clinical use (Mulder et al., 2011). Also, as happens with other 
chemotherapeutic agents, the development of resistance to these GF-based agents has 
already been reported (Giaccone & Wang, 2011). For these reasons, it is important to 
continue the search for new therapeutic strategies which could be used in combination in 
order to enhance the efficacy of GF-related targeted agents. In this sense, the therapeutic 
biomodulation of GSH metabolism may hold promise for the improvement of the efficacy of 
anticancer treatments. Many lines of evidence indicate that this may be an effective 
approach to treating cancer: i) the fact that tumor cells are under high levels of oxidative 
stress may represent a great opportunity given that it means they are particularly vulnerable 
to further increases in ROS levels; ii) colon cancer cells contain particularly high levels of 
GSH; iii) GF-induced signal transduction pathways are redox sensitive, and accordingly, 
alterations in cellular GSH content may affect the growth of GF-sensitive cells; and iv) the 
fact that NF-κB is involved in GF-dependent proliferation and that the activity of this 
transcription factor might also be subject to regulation by GSH suggests that depletion of 
cellular GSH could interrupt NF-κB activity and consequently lead to growth inhibition.  
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In this regard, we have recently demonstrated that GSH-induced depletion by BSO or OTZ 
abrogated the growth-promoting effects of GFs in WiDr colon cancer cells (Palomares et al., 
2009). Similarly, other authors have demonstrated that BSO inhibits GSH upregulation 
induced by HGF, thereby blocking its mitogenic effect (Yang et al., 2008) and the protection 
against apoptosis afforded by this factor. It has likewise been reported that BSO interferes 
with EGF-induced proliferation and that extended exposure (for 48 h or more) of cells to 
BSO induces cell death, probably via a necrotic mechanism (Carmona-Cuenca et al., 2006). 
Regarding VEGF, it has also been reported that BSO treatment reverts increased GSH 
activity induced by this factor and, in this way, its vasculoprotective function (Kuzuya et al., 
2001). In contrast, decreased GSH levels produced by BSO have been shown to promote the 
autocrine secretion of VEGF (Sreekumar et al., 2006).  
Thus, the two effects derived from the biomodulation of GSH intracellular content with BSO 
or OTZ, i.e. i) the reversion of the pro-tumor effect of GFs and ii) the enhanced efficacy of 
chemotherapy, may contribute to enhancing the therapeutic benefit of chemotherapy 
treatment. In fact, we have shown that, in the presence of GFs, the combination of either of 
the GSH modulators with chemotherapeutic drugs produced greater anti-tumor activity 
than the cytotoxic drugs alone. Thus, we found that both BSO and OTZ completely reverted 
the resistance (due to the presence of GFs) of WiDr colon cancer cells to 5-FU, a finding 
which holds promise for more successful anticancer treatment, particularly after surgical 
resection of hepatic metastases (Palomares et al., 2009). Indeed, 5-FU activity was enhanced 
by 40% following the addition of GSH modulators. The activity of oxaliplatin was also 
found to be significantly enhanced (by nearly 25%). Moreover, combined therapy with SN-
38 was found to produce the optimal chemotherapeutic combination; thus, OTZ 
pretreatment combined with SN-38 resulted in an increase of almost 70% in the cytotoxic 
activity of SN-38 (Caramés et al., 2010). To this benefit, we must also add the advantage of 
OTZ with respect to BSO, i.e. the selective reduction of GSH levels in tumor cells, protecting 
healthy cells, as mentioned above. 
Other interesting approaches to the GF problem in cancer therapy have been developed. 
Thus, as cell proliferation and differentiation are deregulated in tumor cells, the induction of 
cell differentiation with retinoids could help to neutralize the pro-tumor effect of GFs. The 
mechanisms of action which underlie the effects of retinoids include the activation of 
nuclear retinoic acid receptors (RAR), but also, curiously, the induction of enhanced ROS 
levels (Palomares et al. , 2006) and a direct interaction of retinoids with the GSH-dependent 
protein kinase C, a key regulatory enzyme in signal transduction (Radominska-Pandya et 
al., 2000). In this sense, we have analyzed the effect of all-trans-retinoic acid (ATRA), a well 
known pro-differentiating agent, on the growth-promoting effect of GFs in two tumor 
models. This drug was found to reduce the proliferative rate of RMS (García-Alonso et al., 
2005) and CRC cells (Martínez-Astorquiza et al., 2008), and hindered or completely 
abolished the stimulus produced by serum obtained from hepatectomized rats, and by a 
wide variety of GFs (HGF, VEGF, PDGF, EGF, bFGF). Furthermore, we also found that cells 
cultured in medium containing ATRA do not develop resistance to the drug, and these 
ATRA-preexposed cells responded to subsequent ATRA treatments in the same manner as 
non-treated cells. However, we observed that the antiproliferative effect of ATRA in vitro is 
not permanent: forty eight hours after removing the drug from the culture medium the cells 
recovered their normal proliferative rate (Díaz et al., 2009). Nevertheless, in in vitro studies, 
we found that ATRA did not interfere with the antiproliferative effect of chemotherapeutics 
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drugs, such as 5-FU; moreover, when both drugs were administered together, an additive 
effect was observed (García-Alonso et al., 2010). 
In order to corroborate these findings in vivo, we designed an experimental model in which 
daily intraperitoneal doses of ATRA were administered for two weeks, starting three days 
before a partial hepatectomy was performed in animals bearing liver metastases. These in 
vivo experiments confirmed the efficacy of ATRA in reducing the proliferative rate of tumor 
cells. In rats bearing RMS S4MH liver metastases, the mean number of liver metastases, as 
well as their mean size, were significantly reduced and significantly longer survival was 
achieved. Using this tumor model, we also analyzed the synergistic effect of ATRA with 
commonly used chemotherapeutic agents such as CY. Once again, animals treated with 
ATRA+CY presented a significant reduction in the mean number of liver metastases and 
also an increase in survival compared to animals treated with CY alone. Similar experiments 
were carried out with the murine CC-531 colon cancer cell line, and similar, albeit not so 
dramatic, results were found (unpublished data). Thus, the mean number of liver metastases 
was unmodified by ATRA, but the mean size of the liver foci was significantly reduced, 
suggesting that tumor progression had been retarded. However, survival remained 
unaltered. Regarding drug tolerance, ATRA was well tolerated by the animals, with no 
repercussion on hematological cell counts, serum enzymes or weight gain. These findings 
point to the need to enhance ATRA effects via other mechanisms. In this regard, it has 
recently been shown that the selective COX-2 inhibitor celecoxib, increased the expression of 
RARbeta in human colon cancer cells, as well as sensitivity to ATRA through COX-2-
independent mechanisms (Liu et al., 2010). 
Novel synthetic derivatives of ATRA have been developed recently and examined in clinical 
trials (Sogno et al, 2010). However, these trials involve administration of the drug as a 
conventional chemotherapeutic agent (Kummar et al, 2011). In the light of the above, it is 
apparent that retinoids (or pro-differentiating agents in general) should be tested as a 
complementary treatment, and administered as part of a combined therapy during the early 
postoperative period, when their action would be most effective. Otherwise, it is unlikely 
that significant improvements will be found in patients treated with these agents in 
monotherapy. 
Overall, and in the light of the important role of GFs in tumor recurrence following surgical 
resection of hepatic metastases, the use of GSH modulators and pro-differentiating agents 
seems to hold promise as a novel therapeutic strategy for metastatic CRC, by reversing GF 
pro-tumor effects and improving the efficacy of chemotherapy.  
8. Conclusion 
Growth factors play a pivotal role in the regulation of CRC progression and metastasis. 
They are involved not only in promoting tumor growth, but also in reducing the 
responsiveness of tumor cells to cytotoxic compounds. The mechanisms of action 
underlying GF effects include the redox state of the tumor, in particular GSH metabolism, 
and the level of expression of related enzymes. The biomodulation of GSH metabolism via 
agents such as BSO or OTZ, could reverse the growth-promoting effects of GFs and enhance 
the therapeutic benefit of chemotherapeutic drugs. The use of pro-differentiating agents 
may also represent a promising anti-tumor strategy to block the pro-tumor effects of GFs. 
The development of more effective retinoids, used either alone or preferably in combination 
with other dugs, may also provide more effective anti-tumor benefits. These new types of 
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strategies to neutralize the pro-tumor effects of GFs may well be crucial in the treatment of 
metastatic disease and the prevention of the recurrence of liver metastases arising from 
CRC.  
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